Vanda Pharmaceuticals Inc. VNDA
Analyst Ratings
- Consensus
- Buy — 4 Buy · 1 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $13.70 (+198.2% upside)
Key Stats
- Today's Range
- $4.44 – $4.64
- 50-Day Range
- $4.43 – $5.64
- 52-Week Range
- $4.27 – $9.94
- Volume
- 468K shs
- Average Volume
- 970K shs
- Market Cap
- $273.29 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 2.58%
- Days to Cover
- 3.94
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Related Stocks
Compare head-to-head: VNDA vs LLY·VNDA vs JNJ·VNDA vs ABBV·VNDA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.